1. Home
  2. EXAS

EXAS

Exact Sciences Corporation

Logo Exact Sciences Corporation

Health Care

Medical Specialities

Nasdaq

as 04-23-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.

Founded: 1995 Country:
United States
United States
Employees: N/A City: MADISON
Market Cap: 13.0B IPO Year: N/A
Target Price: $91.14 AVG Volume (30 days): 2.4M
Analyst Decision: Strong Buy Number of Analysts: 15
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.13 EPS Growth: N/A
52 Week Low/High: $56.05 - $100.77 Next Earning Date: 05-08-2024
Revenue: $2,499,766,000 Revenue Growth: 19.93%
Revenue Growth (this year): 15.61% Revenue Growth (next year): 14.05%

Share on Social Networks: